【华西医药】科伦博泰生物(6990):商业化多点开花,核素偶联药物获批临床

华西研究
Apr 03

“华西研究”小程序全面升级!专业研值,一镜到底!华西医药根据公司公告,截至2024年12月31日止年度,公司收入19.33亿元人民币,同比增长25.5%;年度亏损2.67亿元,上年同期亏损5.74亿元;调整后年度亏损1.18亿元,上年同期亏损4.5亿元。同时,根据公告公司已于2025年3月25日收到NMPA批准SKB107新药临床试验申请的临床试验通知书。SKB107是由公司及西南医大附属医院核...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10